Cytomegalovirus (CMV) has been implicated as a factor in immunosenescence, including poor antibody response to vaccination and higher immune activation and inflammation. Some people may be more or less vulnerable to the negative effects of CMV. The present investigation tested the effects of beta-blocker use and chronological age on the associations between CMV and immunity in adults aged 60-91 (N = 98; 69% CMV seropositive) who were administered the trivalent influenza vaccine for up to 5 years. Peak antibody response, corrected for baseline, and spring (persistent) antibody response, corrected for peak, were assessed, as well as beta-2 microglobulin (b2l) and interleukin-6 (IL-6). In multi-level models with years at Level 1 and people at Level 2, CMV serostatus did not predict peak antibody response, but there was a 3-way interaction between CMV serostatus, age, and beta-blockers. Age was negatively associated with peak antibody, but only among adults who were CMV seropositive and taking beta-blockers. CMV seronegative adults who were not taking beta-blockers had the highest antibody persistence. CMV serostatus was not associated with b2l or IL-6. Results suggest that CMV+ serostatus may negatively compromise antibody response to a greater degree than inflammatory markers in older adults. Furthermore, older adults who take beta-blockers may be more vulnerable to negative effects of age and CMV on peak antibody response, perhaps by virtue of their underlying health condition.
Introduction
Cytomegalovirus (CMV) is an epidemic latent herpesvirus with age-related prevalence, ranging from 40% (18-24 years old) to over 90% (75-80 years old) (Badami et al., 2009) . Unlike other herpesviruses, CMV is rarely associated with a symptomatic acute infection in immunocompetent hosts. It has been suggested that CMV co-evolved with its hosts, resulting in a relatively benign infection (Britt, 2008) . However, CMV is not entirely benign. Latent CMV infection may have consequences for the aging immune system, as CMV is thought to drive immune senescence (Koch et al., 2007) . Consequences include a high percentage of senescent T (CD8+CD28À or CD8+CD57+) and natural killer (NK; CD56 dim CD57+) cells in blood (Lopez-Vergès et al., 2011; Olsson et al., 2001; Wang et al., 1993) . The cytokine profile of senescent cells is more proinflammatory than non-senescent cells (Effros, 2012; Effros et al., 2005) . CMV antibody titers correlate with proinflammatory cytokines in serum, as well as monocyte activation (de Pablo-Bernal et al., 2015; Trzonkowski et al., 2003) . Ultimately, enhanced ''inflammaging" due to CMV could increase risk for multiple health problems of older adulthood (Ershler and Keller, 2000; Frasca and Blomberg, 2016) . Importantly, senescence-associated immune changes have also been framed as immune adaptation, such that the sustained inflammatory state of older adults' innate immune system may be the necessary prerequisite for an acceptable level of functioning of the adaptive immune response (Fulop et al., 2016) . Nevertheless, the absolute number of senescent cells is so much increased that they themselves may cause pathology as a result of their higher ability to produce inflammatory mediators (Pawelec et al., 2010) .
CMV may also contribute to poor antibody production by B cells (Simons and Reynolds, 1990) . CMV antibody titers correlated negatively with antibody response to influenza vaccination among both older (65-99 years) and younger (19-40 years) adults (Trzonkowski et al., 2003) . However, in another sample of older (62-89 years) and younger (20-30 years) adults, CMV+ serostatus
